Rybelsus, a breakthrough medication for Type 2 diabetes, influences the digestive system significantly. Users often notice changes in their gastrointestinal function shortly after starting treatment. This oral GLP-1 receptor agonist promotes insulin secretion while reducing glucagon release, leading to better blood sugar control. However, its impact on the digestive rhythm…